Barzolvolimab

巴佐利单抗

Report date: 2026/05/02 20:00:18

Base Information

Drug NameBarzolvolimab
Drug Alias NameCDX-0159
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionStem cell growth factor receptor inhibitors
TargetsStem cell growth factor receptor
Therapy Area/IndicationsSymptomatic DermographismPrurigo NodularisChronic Urticaria +[7
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[37
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
China Registration ClassN/A

Develop Information

Active CompaniesCelldex Therapeutics
Inactive CompaniesN/A
Active IndicationsSymptomatic DermographismPrurigo NodularisChronic Urticaria +[7
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A